Destaques

Estudo randomizado | Seguimento pós-parto de 72 semanas de dolutegravir vs. efavirenz iniciado na gestação.

5 Ago, 2022 | 17:40h

72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study – The Lancet HIV

Conteúdos relacionados:

WHO Recommends Dolutegravir as Preferred HIV Treatment Option in All Populations

Week 96 results from a RCT: Efficacy and safety of dolutegravir or darunavir combined with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection.

RCT: Efficacy and safety of switching to the 2-drug regimen Dolutegravir/Lamivudine vs. continuing a 3- or 4-Drug regimen for maintaining virologic suppression in adults living with HIV-1.

RCT: Low-cost, easy to take antiretroviral treatment based on Dolutegravir as first- or second-Line therapy found to be non-inferior to standard care for treating HIV-1 infection in children.

RCT: Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV.

Randomized controlled trial compared three antiretroviral regimens started in pregnant women with HIV

Randomized Trial: Switching to Dolutegravir/Lamivudine Two-Drug Regimen Noninferior to Continuing a Tenofovir Alafenamide–Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1

 

---

Estudo de caso-controle | Uso ambulatorial de macrolídeo oral está associado com risco aumentado de perda de audição neurossensorial em crianças, adolescentes e jovens adultos.

5 Ago, 2022 | 17:39h

Association of Outpatient Oral Macrolide Use With Sensorineural Hearing Loss in Children, Adolescents, and Young Adults – JAMA Otolaryngology-Head & Neck Surgery (link para o resumo – $ para o texto completo)

Comentário: Kids’ Hearing Loss Associated With Common Antibiotics — Children and teens with sensorineural hearing loss more often macrolide users – MedPage Today (necessário cadastro gratuito)

 

---

Estudo de coorte | Risco de overdose de opioide é aumentado pelo uso concomitante de oxicodona e inibidores seletivos de recaptação de serotonina que inibem o metabolismo da oxicodona.

5 Ago, 2022 | 17:37h

Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors – JAMA Network Open

Comentário do autor: Taking certain opioids while on commonly prescribed antidepressants may increase the risk of overdose – The Conversation

 

Comentário no Twitter

This cohort study found that concomitant use of oxycodone with potent CYP2D6-inhibiting serotonin reuptake inhibitors (SSRIs, eg. fluoxetine or paroxetine) is associated with an increased risk of overdose. https://t.co/Eol89RHWAu

— JAMA Network Open (@JAMANetworkOpen) February 24, 2022

 

---

Em um estudo de coorte com seguimento mediano de 23,2 anos, níveis baixos e muito baixos de LDL-colesterol foram associados com risco aumentado de mortalidade cardiovascular na população geral.

5 Ago, 2022 | 17:35h

Association of Low‐Density Lipoprotein Cholesterol Levels with More than 20‐Year Risk of Cardiovascular and All‐Cause Mortality in the General Population – Journal of the American Heart Association

 

---

M-A | Eficácia da doxiciclina para pneumonia adquirida na comunidade leve a moderada em adultos.

5 Ago, 2022 | 17:34h

Efficacy of Doxycycline for Mild-to-moderate Community-acquired Pneumonia in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials – Clinical Infectious Diseases (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

🆕⚡⚡Systematic Review and Meta-analysis of Randomized Controlled Trials @CIDJournal
Efficacy of Doxycycline for Mild-to-moderate CAP in Adults
The efficacy of doxycycline was comparable to macrolides or fluoroquinolones in mild-moderate CAP #IDTwitter https://t.co/L7UBBUc4Dm

— Antibiotic Steward Bassam Ghanem🆔⚡ (@ABsteward) July 29, 2022

 

---

Estudo de coorte | Cirurgia bariátrica está associada a aumento no risco de casamentos ou divórcios.

5 Ago, 2022 | 17:28h

Comunicado de imprensa: Bariatric Surgery Linked to Doubling Chance of Marriage or Divorce – University of Pittsburgh

Estudo original: Changes in Marital Status Following Roux-en-Y Gastric Bypass and Sleeve Gastrectomy: A US Multicenter Prospective Cohort Study – Annals of Surgery Open

Comentário: Spouse Getting Weight Loss Surgery? Your Marriage Might Be in Trouble – HealthDay

 

---

Diretriz | Prevenção da obesidade em mulheres de meia-idade.

5 Ago, 2022 | 16:51h

Preventing Obesity in Midlife Women: A Recommendation From the Women’s Preventive Services Initiative – Annals of Internal Medicine

Comunicado de imprensa: Women’s Preventive Services Initiative issues guidelines for preventing obesity in midlife women – American College of Physicians

Comentário: Counseling Can Prevent Obesity in Normal, Overweight Women – HealthDay

 

Comentário no Twitter

New guidelines aim to prevent #obesity in midlife women. @TheWPSI recommends counseling to prevent weight gain in all women at normal or overweight BMI. Full text available at https://t.co/P8VwBWIHXe @CedarsSinai @acog pic.twitter.com/YxTQVgXj59

— Annals of Int Med (@AnnalsofIM) August 2, 2022

 

---

Estudo RECOVERY | Baricitinibe em pacientes hospitalizados com COVID-19.

5 Ago, 2022 | 16:50h

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – The Lancet

Comentário convidado: Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality – The Lancet

Conteúdos relacionados:

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial – medRxiv

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial – The Lancet Respiratory Medicine

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – medRxiv

WHO recommends two new drugs to treat COVID-19 – World Health Organization

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial – The Lancet Respiratory Medicine

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 – New England Journal of Medicine

 

Comentário no Twitter

New @TheLancet
The largest trial of baricitinib, a JAK-inhibitor drug repurposed via #AI data mining, reduced Covid mortality and the overall reduction consistent with 8 previous RCTs (~20%)https://t.co/5fHDBBvm3Q pic.twitter.com/GDFzcU26H6

— Eric Topol (@EricTopol) July 29, 2022

Sob licença de Creative Commons Attribution (CC BY 4.0)

 

---

M-A | Resposta à monoterapia farmacológica aguda para transtornos depressivos maiores em estudos randomizados e placebo-controlados.

5 Ago, 2022 | 16:48h

Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis – The BMJ

 

---

Estudo de coorte | Associação entre crises de gota e eventos cardiovasculares subsequentes.

5 Ago, 2022 | 16:47h

Association Between Gout Flare and Subsequent Cardiovascular Events Among Patients With Gout – JAMA (gratuito por tempo limitado)

Editorial: Cardiovascular Events and Gout Flares – JAMA (gratuito por tempo limitado)

Comunicado de imprensa: Flare-ups of gout are linked to heart attack and stroke – University of Nottingham

Comentário: Association Between Gout Flare and Subsequent Cardiovascular Events – American College of Cardiology

 

---